Osthole improves fat milk-induced fatty liver in rats: Modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression

Planta Medica

Volumn 73, Issue 8, 2007, Pages 718-724

  Zhang, Yan ^a   Xie, Meilin ^a   Xue, Jie ^a   Gu, Zhenlun ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Apiaceae; Cnidium monnieri (L.) cusson; Fatty liver; Lipid metabolism; Osthole; PPAR

Indexed keywords

CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CNIDIUM MONNIERI EXTRACT; MESSENGER RNA; MILK FAT; OSTHOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APIALES; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FATTY LIVER; GENE EXPRESSION; GENE TARGETING; HYPERLIPIDEMIA; LIPID STORAGE; LIPOGENESIS; LIVER; LIVER CELL; LIVER HISTOLOGY; LIVER WEIGHT; MALE; NONHUMAN; RAT; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASTRUCTURE;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL; CNIDIUM; COUMARINS; DIETARY FATS; DNA PRIMERS; FATTY LIVER; FRUIT; GENE EXPRESSION REGULATION; MALE; MILK; PHYTOTHERAPY; PLANT EXTRACTS; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TRIGLYCERIDES;

APIACEAE; CNIDIUM MONNIERI; RATTUS;

EID: 34547813175     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981552     Document Type: Article

References (24)

1. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5: 27-42.
2. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1): S17-29.
3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
4. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-7.
5. Jones PS, Savory R, Barratt P, Bell AR, Gray TJ, Jenkins NA et al. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem 1995; 233: 219-26.
6. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
7. Lian QS. Progress in study of chemical constituents and pharmacological effects of the fruit of Cnidium monnieri. Chin Med Mater 2003; 26: 141-4.
8. Song F, Xie ML, Zhu LJ, Zhang KP, Xue J, Gu ZL. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals. World J Gastroenterol 2006; 12: 4359-63.
9. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104.
10. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
11. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-33.
12. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-7.
13. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc J 2005; 172: 899-905.
14. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 93-230.
15. Xu Y, Rito CJ, Etgen GJ, Ardecky RJ, Bean JS, Bensch WR et al. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem 2004; 47: 2422-5.
16. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 2004; 27: 1324-9.
17. Farese RV Jr, Cases S, Smith SJ. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 2000; 11: 229-34.
18. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001; 21: 1840-5.
19. Cheema SK, Agellon LB. The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha. J Biol Chem 2000; 275: 12 530-6.
20. Waterman IJ, Zammit VA. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 2002; 51: 1708-13.
21. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chm 2004; 279: 45 512-8.
22. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther 2004; 310: 417-24.
23. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue-and inducer-specific manner. J Biol Chem 1998; 273: 16710-4.
24. Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A et al. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 2005; 280: 1224-9.